Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Vertex Pharmaceuticals
(NQ:
VRTX
)
442.70
-4.18 (-0.94%)
Streaming Delayed Price
Updated: 3:42 PM EDT, May 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Vertex Pharmaceuticals
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
42
43
Next >
3 Stocks Savvy Investors Are Buying Hand Over Fist
October 06, 2022
These high-flying stocks are defying the bear market.
Via
The Motley Fool
Large Cap Biopharmaceuticals: Core Holdings For Your Portfolio
October 03, 2022
Now that some clarity is apparent for drug pricing legislation you should have a few large-cap biopharmaceutical stocks in your portfolio.
Via
Talk Markets
Bluebird Bio Offers World's Most Expensive Drugs, But Uncertainty Looms Over Its Financial Future
October 03, 2022
Bluebird Bio Inc (NASDAQ: BLUE) is about to become the seller of the two most expensive drugs in the U.S. and probably the world. The price tag of $3 million is already facing backlash.
Via
Benzinga
Vertex, Gene-Editing Leader, Heads 5 Resilient Stocks In Bear Market
October 01, 2022
Vertex flashed a buy signal on positive gene-editing news.
Via
Investor's Business Daily
Stock Market Falls, S&P 500 Hits Bear Lows; Biogen, Nike, Micron Are Key Movers: Weekly Review
September 30, 2022
The major indexes fell, with the S&P 500 breaking below bear market lows.
Via
Investor's Business Daily
Vertex Pharma's Flagship Cystic Fibrosis Drug Scores FDA Approval For Infants
September 02, 2022
Via
Benzinga
MaxCyte Inks Platform License With Vertex For Gene-Editing Program For Rare Blood Disorders
September 28, 2022
MaxCyte Inc (NASDAQ: MXCT) has signed a
Via
Benzinga
Why Low Volatility ETFs Are Beating The Market
September 27, 2022
Low volatility investing is back in vogue since the market environment remains extremely challenging.
Via
Talk Markets
Intercept Pharmaceutical Stock Sees RS Rating Rise To 91
September 27, 2022
Intercept Pharmaceutical shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
Why Is Crispr Therapeutics (CRSP) Stock Up Today?
September 27, 2022
Crispr Therapeutics (CRSP) stock is gaining on Tuesday after the FDA granted exagamglogene autotemcel (exa-cel) a rolling review.
Via
InvestorPlace
Crispr Stock Jumps After Unveiling Timeline For FDA Submission Of First-Ever CRISPR Drug
September 27, 2022
Crispr and Vertex nailed down the timeline for their blood diseases gene editor.
Via
Investor's Business Daily
Why CRISPR Therapeutics Stock Is Rising Today
September 27, 2022
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Tuesday after the company and Vertex Pharmaceuticals Inc (NASDAQ: VRTX) announced the U.S.
Via
Benzinga
The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market
September 27, 2022
Despite the ongoing worries on Wall Street, these are the best stocks to buy to play the hidden bull market.
Via
InvestorPlace
Recursion Pharma Stock Earns Relative Strength Rating Upgrade; Hits Key Benchmark
September 26, 2022
Recursion Pharma stock cleared a key performance benchmark Monday, with its Relative Strength Rating upgraded to 89 from 76 the day before.
Via
Investor's Business Daily
Can Healthcare Stocks Continue To Outperform?
September 26, 2022
Large-cap healthcare and biotech stocks have been resilient amidst the market turmoil caused by rising rates and the global geopolitical crisis.
Via
Talk Markets
S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market
September 24, 2022
Eli Lilly leads medical stocks setting up and showing relative strength.
Via
Investor's Business Daily
Pain Therapeutics Stock Shows Rising Price Performance With Jump To 97 RS Rating
September 23, 2022
Pain Therapeutics sees its Relative Strength Rating enter the elite 90-plus level.
Via
Investor's Business Daily
7 Growth Stocks to Buy During a Stock Market Crash
September 23, 2022
A stock market crash will only strengthen the outlook of these companies, making them good growth stocks to buy.
Via
InvestorPlace
$1000 Invested In This Stock 15 Years Ago Would Be Worth $7,400 Today
September 23, 2022
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 8.2% on an annualized basis producing an average annual return of 14.17%. Currently, Vertex Pharmaceuticals...
Via
Benzinga
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
September 16, 2022
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema.
Via
Investor's Business Daily
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
September 15, 2022
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.
Via
Investor's Business Daily
Akero Therapeutics Stock Joins Elite Club Of Stocks With RS Ratings Over 90
September 14, 2022
Akero Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 73 to 99.
Via
Investor's Business Daily
Biotech Stocks Stand to Benefit as Biden Announces Support for Industry
September 12, 2022
President Biden has announced a new initiative to help U.S. biotech producers grow. Here's what this news means for biotech stocks.
Via
InvestorPlace
Sage Therapeutics Stock Scores Relative Strength Rating Upgrade
September 09, 2022
On Friday, Sage Therapeutics stock received a positive adjustment to its Relative Strength (RS) Rating, from 86 to 91.
Via
Investor's Business Daily
Amylyx Pharmaceuticals Stock Sees Relative Strength Rating Rise To 98
September 09, 2022
Amylyx Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating improve to 98, up from 83 the day before.
Via
Investor's Business Daily
Neurocrine Leads 5 Stocks To Watch In Sickly Market
September 03, 2022
Neurocrine Biosciences leads five medical stocks showing resilience.
Via
Investor's Business Daily
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
September 02, 2022
Via
Benzinga
Agios Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
September 02, 2022
Agios Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an increase from 65 to 93.
Via
Investor's Business Daily
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years
September 02, 2022
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 6.64% on an annualized basis producing an average annual return of 17.25%. Currently, Vertex Pharmaceuticals...
Via
Benzinga
Legend Biotech Stock Joins Elite Club Of Stocks With RS Ratings Over 90
September 01, 2022
On Thursday, Legend Biotech stock had its Relative Strength (RS) Rating upgraded to 91, up from 87 a day earlier.
Via
Investor's Business Daily
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
42
43
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.